In a serendipitous leap forward for maternal health, researchers at the University of Michigan Taubman Medical Research Institute have identified a potential biological trigger for preeclampsia, a notoriously enigmatic and life-threatening pregnancy complication. The breakthrough, published in the prestigious journal Circulation on August 6, 2026, points to the dysregulation of a single gene—VGLL3—as the root cause of the disorder, potentially unlocking the door to the first true cure for a condition that claims an estimated 70,000 lives globally each year.

A Lightbulb Moment in an Unlikely Lab

The discovery did not originate in an obstetrics ward, but in a dermatology lab. Dr. Johann Gudjonsson, a professor of immunology, was initially investigating why autoimmune diseases disproportionately affect women. Because many of these disorders manifest dermatological symptoms, his team was heavily focused on skin tissue. However, a chance hallway conversation with Dr. Ashley Bartell, an OB-GYN specializing in cardio-obstetrics, shifted the trajectory of his career.

Bartell noted the clinical difficulty in distinguishing between severe autoimmune flare-ups and preeclampsia. Intrigued, Gudjonsson hypothesized that the genetic markers he was observing in women's skin might also be active in the placenta. He brought on Dr. Olesya Plazyo, an immunologist with a background in placental biology, and the cross-disciplinary team dove into the uncharted territory of maternal-fetal medicine.

Cracking the VGLL3 Code

Using advanced single-cell RNA sequencing, the team compared healthy placental tissue with preeclamptic samples. They discovered that VGLL3—a transcription cofactor that acts as a biological on/off switch—was wildly overexpressed in the trophoblast cells of preeclamptic placentas. These unique cells, which only exist during pregnancy, are responsible for guiding blood vessel growth and interacting with the mother's immune system.

"I think of it almost like a thermostat that is stuck at the high level. These are all normal biological processes that VGLL3 regulates, but then sends into overdrive when it's dysregulated." — Dr. Johann Gudjonsson, University of Michigan

In mouse models, the results were striking. Overexpression of VGLL3 induced severe hypertension mirroring human preeclampsia. Conversely, inhibiting the protein or deleting the VGLL3 gene resulted in completely normal, healthy pregnancies. The gene essentially controls pathways involved in vascular development and immune response; when it goes haywire, it floods the mother's system with sFLT-1, a protein biomarker known to cause catastrophic blood vessel dysregulation.

The Path to Precision Obstetrics

Currently, the only "cure" for preeclampsia is delivery of the fetus, often resulting in dangerous preterm births. Even postpartum, mothers face a lifelong elevated risk of cardiovascular disease and stroke. This genetic breakthrough offers a tangible path toward targeted therapeutics that could silence the VGLL3 overexpression, effectively preventing the disease from taking hold.

While human clinical trials targeting VGLL3 are still on the horizon, the identification of this molecular mechanism represents a monumental paradigm shift. As Dr. Paige Porrett, a uterus transplant surgeon at UAB, quipped: "What happens when a transplant surgeon, a dermatologist, a cardiologist, and an OB-GYN walk into a bar? Oh, we figured out preeclampsia!" For the millions of women navigating the precarious journey of pregnancy, this cross-disciplinary triumph may soon turn a fatal mystery into a manageable, and ultimately preventable, condition.

Further reading: Read the original report on National Geographic